Edwards Lifesciences Corporation EW SPX
Healthcare · Medical Devices · United States
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
READ MORE ›$86.47
+10.55% 1Y
Market & Price
Market Cap
$49.79B
Current Price
$86.47
High / Low (52W)
$87.54 / $72.65
Beta
0.87
Valuation
Stock P/E
46.74
Industry PE
23.65
Forward P/E
25.70
PEG Ratio
2.07
Book Value
$17.90
Price to Book
4.83
P/S
7.90
EV/EBITDA
24.60
Dividend Yield
-
Profitability & Returns
ROCE
10.88%
ROE
10.46%
ROA
8.27%
Profit Margin
17.39%
Op Margin
31.22%
EPS (Latest Qtr)
$0.66
EPS (TTM)
$1.85
Balance Sheet & Liquidity
Debt/Equity
0.07
Quick Ratio
3.30
Current Ratio
4.42
Debt
$702.90M
Total Assets
$13.70B
Current Assets
$6.74B
Working Capital
$4.93B
Ownership
Promoter Holding
0.18%
Chg in Prom Hold
-
FII / Inst Holding
94.06%
Chg in FII Hold
-0.06%
Financial Snapshot
Enterprise Value
$46.82B
Total Revenue (TTM)
$6.30B
EBITDA
$1.90B
Free Cash Flow
$902.14M
Operating Cash Flow
$1.36B
Shares Outstanding
575.80M
Gross Margin
77.87%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
10.77%
Profit 5Y
-10.98%
Revenue (YoY)
16.70%
Earnings (YoY)
8.20%
PROS
- Compounding revenue at 10.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -11.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EW Edwards Lifesciences Corporation SPX | 86.47 | 46.74 | $49.79B | - | 10.88% | 10.46% | 10.77% | -10.98% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 883.50M | 841.80M | 821.50M | 888.50M | 894.80M | 943.70M | 906.60M | 977.70M | 993.00M | 1.09B | 1.09B | 1.17B | 1.13B | 925.00M | 1.14B | 1.19B | 1.22B | 1.38B | 1.31B | 1.34B | 1.37B | 1.32B | 1.22B | 1.28B | 1.24B | 1.27B | 1.33B | 1.37B | - | - | 1.41B | 1.53B | 1.55B | 1.57B | 1.65B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 301.60M | 344.40M | 345.20M | 343.00M | 362.60M |
| Gross Profit | 495.20M | 517.00M | 556.80M | 538.00M | 554.50M | 667.90M | 630.70M | 608.20M | 653.20M | 661.20M | 697.50M | 681.70M | 743.00M | 761.20M | 782.90M | 801.60M | 887.90M | 863.60M | 686.80M | 859.90M | 895.40M | 923.20M | 1.04B | 998.50M | 1.04B | 1.10B | 1.07B | 992.30M | 1.03B | 992.80M | 1.02B | 1.04B | 1.09B | - | - | 1.11B | 1.19B | 1.21B | 1.23B | 1.29B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 701.20M | 756.90M | 782.80M | 856.30M | 771.30M |
| Operating Income | - | - | - | - | - | 298.30M | 241.00M | 214.00M | - | 252.50M | 252.10M | 248.90M | - | 274.20M | 267.50M | 294.30M | - | 358.10M | -169.70M | 357.80M | - | 383.50M | 542.10M | 390.30M | 438.80M | 459.50M | 402.40M | 388.40M | 263.50M | 365.90M | - | 349.00M | 366.50M | - | - | 409.90M | 430.90M | 425.10M | 370.30M | 514.70M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 446.50M | 469.00M | 464.30M | 70.10M | 555.60M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 433.90M | 400.20M | 348.40M | 90.40M | 459.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70.30M | 64.30M | 56.10M | 26.20M | 78.30M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 406.40M | 343.50M | 340.50M | 307.10M | 384.90M | 369.90M | 351.90M | 366.30M | - | - | 358.00M | 329.80M | 291.10M | 91.20M | 380.70M |
| Diluted EPS | 0.64 | 0.66 | 0.58 | 0.65 | 0.73 | 1.06 | 0.86 | 0.79 | -0.01 | 0.96 | 1.32 | 1.06 | 0.03 | 0.39 | 0.38 | 0.43 | 0.44 | 0.49 | -0.20 | 0.52 | 0.49 | 0.54 | 0.78 | 0.54 | 0.59 | 0.65 | 0.55 | 0.56 | 0.50 | 0.63 | 0.61 | 0.58 | 0.61 | - | - | 0.61 | 0.56 | 0.50 | 0.16 | 0.66 |
| R&D Expense | - | 101.80M | 112.50M | 113.00M | - | 128.70M | 134.40M | 142.90M | - | 143.20M | 154.10M | 161.80M | - | 171.40M | 191.90M | 195.50M | - | 187.40M | 182.10M | 195.50M | - | 207.00M | 225.30M | 238.00M | 228.60M | 250.80M | 233.60M | 261.20M | 243.70M | 242.80M | - | 256.70M | 271.80M | 253.40M | - | 254.60M | 276.20M | 280.70M | - | 263.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 2.96B | 3.44B | 3.72B | 4.35B | 4.39B | - | 4.46B | 5.01B | 5.44B | 6.07B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 723.70M | 978.40M | 1.12B | 1.33B |
| Gross Profit | 818.10M | 922.30M | 1.04B | 1.19B | 1.41B | 1.53B | 1.70B | 1.88B | 2.17B | 2.56B | 2.78B | 3.23B | 3.31B | - | 3.74B | 4.03B | 4.32B | 4.73B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.20B | 2.55B | 2.84B | 3.10B |
| Operating Income | - | - | - | - | - | - | - | - | 751.20M | 1.09B | 748.20M | 1.15B | 897.60M | - | 1.54B | 1.49B | 1.48B | 1.64B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.68B | 1.53B | 1.72B | 1.45B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.20M | 17.60M | 19.80M | 20.40M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.52B | 1.37B | 1.55B | 1.27B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 195.50M | 152.40M | 152.10M | 216.90M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.52B | 1.40B | 4.17B | 1.07B |
| Diluted EPS | 1.10 | 1.95 | 1.83 | 1.98 | 2.46 | 1.71 | 3.74 | 2.25 | 2.61 | 2.70 | 1.13 | 1.64 | 1.30 | - | 2.44 | 2.30 | 6.97 | 1.83 |
| R&D Expense | 139.20M | 175.50M | 204.40M | 246.30M | 291.30M | 323.00M | 346.50M | 382.90M | 442.20M | 552.60M | 622.20M | 752.70M | 760.70M | 903.10M | 843.60M | 962.90M | 1.05B | 1.08B |
Compounded Sales Growth
| 5 Years: | 10.77% |
| 1 Year: | 16.70% |
Compounded Profit Growth
| 5 Years: | -10.98% |
| 1 Year: | 8.20% |
Stock Price Performance
| 1 Year: | +10.55% |
| 6 Months: | -0.40% |
| 3 Months: | +0.00% |
| 1 Month: | +6.46% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Mar 2011 | Jun 2011 | Sep 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.62B | 1.77B | - | - | - | 1.98B | 2.22B | 2.71B | 3.52B | 4.06B | 4.51B | 5.67B | 5.32B | 6.49B | 7.24B | - | 8.29B | 9.36B | 13.06B | 13.70B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.10B | 4.04B | 6.29B | 6.74B |
| Cash & Equivalents | 141.80M | 218.70M | 334.10M | 396.10M | 325.20M | 175.60M | 244.00M | 171.20M | 310.90M | 420.40M | 653.80M | 718.40M | 930.10M | 818.30M | 714.10M | 1.18B | 1.18B | - | 769.00M | 1.13B | 3.05B | 2.94B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 875.50M | 903.50M | 1.09B | 1.13B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 643.00M | 771.50M | 609.10M | 659.60M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.66B | - | 2.49B | 2.64B | 2.99B | 3.36B |
| Current Liabilities | - | - | 290.50M | 337.80M | - | - | - | 335.20M | 347.40M | 345.60M | 426.10M | 476.20M | 532.50M | 1.42B | 876.60M | 902.40M | 893.90M | - | 1.02B | 1.20B | 1.51B | 1.81B |
| Long Term Debt | - | - | - | - | - | - | - | - | 189.30M | 593.10M | 598.10M | 596.90M | 822.30M | 438.40M | 593.80M | 594.40M | 595.00M | - | 596.30M | 597.00M | 597.70M | 598.30M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 691.30M | 685.10M | 700.00M | 705.40M |
| Total Equity | - | 878.80M | 1.16B | 1.31B | - | - | - | 1.33B | 1.47B | 1.54B | 2.19B | 2.50B | 2.62B | 2.96B | 3.14B | 4.15B | 4.57B | - | 5.81B | 6.65B | 10.00B | 10.34B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 646.30M | 650.50M | 654.80M | 658.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 153.20M | 165.30M | 251.40M | - | - | - | - | 549.70M | 704.40M | 1.00B | 926.70M | 1.18B | 1.05B | - | 1.22B | 895.80M | 542.30M | 1.60B |
| Investing Cash Flow | 58.80M | 40.10M | -61.50M | - | - | - | - | -316.10M | -211.70M | -647.20M | 76.70M | -595.80M | -531.10M | - | 252.30M | 173.80M | 2.31B | -712.90M |
| Financing Cash Flow | -134.10M | -91.80M | -103.90M | - | - | - | - | -158.60M | -268.50M | -473.20M | -1.10B | -115.60M | -486.90M | - | -1.58B | -711.00M | -983.00M | -956.80M |
| Capital Expenditure | -50.60M | -64.00M | -61.80M | -76.60M | -109.00M | -109.00M | -82.90M | -102.70M | -176.10M | -168.10M | -238.70M | -254.40M | -407.00M | - | -264.80M | -266.30M | -282.40M | -260.20M |
| Free Cash Flow | 102.60M | 101.30M | 189.60M | - | - | - | - | 447.00M | 528.30M | 832.60M | 688.00M | 928.50M | 647.30M | - | 953.40M | 629.50M | 259.90M | 1.33B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -114.00M | 358.60M | 1.87B | -74.50M |
| Share Buybacks | 306.50M | 95.50M | 200.00M | 303.40M | 344.10M | 496.90M | 300.90M | 280.10M | 662.30M | 763.30M | 795.50M | 263.30M | 625.40M | 512.80M | 1.73B | 879.60M | 1.16B | 893.40M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 73.1% | 74.5% | 74.8% | 74.4% | 75.4% | - | 83.8% | 80.5% | 79.5% | 78.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | 25.3% | 31.7% | 20.1% | 26.4% | 20.5% | - | 34.5% | 29.7% | 27.2% | 27.0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.1% | 28.0% | 76.7% | 17.7% |
| ROE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.2% | 21.1% | 41.8% | 10.4% |
| ROCE % | - | - | - | - | - | - | - | - | 18.9% | 25.7% | 16.8% | 20.5% | 14.2% | - | 21.2% | 18.2% | 12.8% | 13.8% |
Shareholding Pattern
Insiders
0.18%
Institutions
94.06%
Public Float
94.23%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.13% | 52.59M | $4.55B |
| 2 | Vanguard Capital Management LLC | 6.55% | 37.73M | $3.26B |
| 3 | Vanguard Portfolio Management LLC | 4.59% | 26.41M | $2.28B |
| 4 | State Street Corporation | 4.57% | 26.30M | $2.27B |
| 5 | Wellington Management Group, LLP | 3.82% | 22.01M | $1.90B |
| 6 | JPMORGAN CHASE & CO | 3.78% | 21.74M | $1.88B |
| 7 | Bank Of New York Mellon Corporation | 2.91% | 16.74M | $1.45B |
| 8 | FMR, LLC | 2.52% | 14.50M | $1.25B |
| 9 | Geode Capital Management, LLC | 2.28% | 13.13M | $1.14B |
| 10 | Jennison Associates LLC | 2.27% | 13.07M | $1.13B |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EW
No recent headlines available.